glp-1/glp-2 dual agonist and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data The Emerging Role of Dual
Description
Gastrointestinal symptoms were the most common side effects

This work was supported by the Lundbeck Foundation (fellowship R238-2016-2859), the BioInnovation Institute (grant number NNF20OC0063538) and the Novo Nordisk Foundation (grant numbers NNF17OC0026114 and NNF22OC0073778)

2023 Aug;402(10401):52944

2017;96(14):e6558

Regular follow-up during the first three months of treatment allows for timely intervention if side effects become problematic, maximizing the likelihood of successful long-term weight management while maintaining quality of life throughout the treatment journey

Peak Wellness versus other telehealth GLP-1 providers The telehealth GLP-1 market has exploded
